Cargando…
Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
BACKGROUND: Imatinib mesylate (IM) is the preferred treatment for the majority of patients with metastatic gastrointestinal stromal tumour (GIST). Low trough IM concentration (C(min)) values have been associated with poor clinical outcomes in GIST patients. However, there are few studies of repeated...
Autores principales: | Hompland, Ivar, Bruland, Øyvind Sverre, Ubhayasekhera, Kumari, Bergquist, Jonas, Boye, Kjetil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157085/ https://www.ncbi.nlm.nih.gov/pubmed/27999655 http://dx.doi.org/10.1186/s13569-016-0062-2 |
Ejemplares similares
-
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
por: Fauske, Lena, et al.
Publicado: (2019) -
Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity
por: Gorunova, Ludmila, et al.
Publicado: (2022) -
Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011) -
Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission
por: Fauske, Lena, et al.
Publicado: (2020) -
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)